An evaluation of the safety of anti-CD19 CAR-T cells manufactured using the CliniMACS Prodigy platform is currently underway in a phase I/II clinical trial enrolling patients with relapsed/refractory NHL. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.